JP2008503585A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008503585A5 JP2008503585A5 JP2007518192A JP2007518192A JP2008503585A5 JP 2008503585 A5 JP2008503585 A5 JP 2008503585A5 JP 2007518192 A JP2007518192 A JP 2007518192A JP 2007518192 A JP2007518192 A JP 2007518192A JP 2008503585 A5 JP2008503585 A5 JP 2008503585A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- alkyl
- cycloalkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 48
- 125000000217 alkyl group Chemical group 0.000 claims 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims 24
- 125000003118 aryl group Chemical group 0.000 claims 22
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 21
- 125000004093 cyano group Chemical group *C#N 0.000 claims 19
- 125000001072 heteroaryl group Chemical group 0.000 claims 19
- 125000003545 alkoxy group Chemical group 0.000 claims 17
- 125000001188 haloalkyl group Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- -1 heterocycloalkyloxy Chemical group 0.000 claims 12
- 125000004438 haloalkoxy group Chemical group 0.000 claims 10
- 125000004104 aryloxy group Chemical group 0.000 claims 8
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 8
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 5
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 4
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 claims 4
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 229940111134 coxibs Drugs 0.000 claims 3
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003018 immunosuppressive agent Substances 0.000 claims 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940124589 immunosuppressive drug Drugs 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 2
- 229960002702 piroxicam Drugs 0.000 claims 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 2
- 125000005493 quinolyl group Chemical group 0.000 claims 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000000884 Airway Obstruction Diseases 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 206010001889 Alveolitis Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 229940122444 Chemokine receptor antagonist Drugs 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063897 Renal ischaemia Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000036284 Rhinitis seasonal Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 125000003302 alkenyloxy group Chemical group 0.000 claims 1
- 125000005133 alkynyloxy group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 239000002559 chemokine receptor antagonist Substances 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 229960000681 leflunomide Drugs 0.000 claims 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 1
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 1
- 229960001639 penicillamine Drugs 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- SDKPSXWGRWWLKR-UHFFFAOYSA-M sodium;9,10-dioxoanthracene-1-sulfonate Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2S(=O)(=O)[O-] SDKPSXWGRWWLKR-UHFFFAOYSA-M 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 claims 1
- 0 **(C=CC=C1S(N2C(C3)CC(*)(CNS(*)(=O)=O)CCC3C2)(=O)=O)C=C1S(*)(=O)=O Chemical compound **(C=CC=C1S(N2C(C3)CC(*)(CNS(*)(=O)=O)CCC3C2)(=O)=O)C=C1S(*)(=O)=O 0.000 description 3
- KMSXGMMRQVOHME-KRWDZBQOSA-N O=S(C(F)(F)F)(N[C@@H](C1)C1(CC1)CCN1S(c1cc(cccc2)c2[n]1S(c1ccccn1)(=O)=O)(=O)=O)=O Chemical compound O=S(C(F)(F)F)(N[C@@H](C1)C1(CC1)CCN1S(c1cc(cccc2)c2[n]1S(c1ccccn1)(=O)=O)(=O)=O)=O KMSXGMMRQVOHME-KRWDZBQOSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58183704P | 2004-06-22 | 2004-06-22 | |
| PCT/US2005/021870 WO2006002133A1 (en) | 2004-06-22 | 2005-06-21 | Cannabinoid receptor ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008503585A JP2008503585A (ja) | 2008-02-07 |
| JP2008503585A5 true JP2008503585A5 (show.php) | 2008-07-10 |
Family
ID=35079285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007518192A Withdrawn JP2008503585A (ja) | 2004-06-22 | 2005-06-21 | カンナビノイドレセプターリガンド |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7750158B2 (show.php) |
| EP (1) | EP1768667B1 (show.php) |
| JP (1) | JP2008503585A (show.php) |
| CN (1) | CN101005838A (show.php) |
| AT (1) | ATE444066T1 (show.php) |
| CA (1) | CA2571058A1 (show.php) |
| DE (1) | DE602005016929D1 (show.php) |
| ES (1) | ES2332416T3 (show.php) |
| MX (1) | MX2007000015A (show.php) |
| WO (1) | WO2006002133A1 (show.php) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101304997A (zh) * | 2005-08-19 | 2008-11-12 | 伊兰医药品股份有限公司 | γ-分泌酶的桥联N-二环磺酰氨基抑制剂 |
| CA2651777A1 (en) * | 2006-05-15 | 2007-11-29 | Merck & Co., Inc. | Pro-drugs of tertiary alcohols |
| CA2674644A1 (en) | 2007-01-10 | 2008-07-17 | F. Hoffmann-La Roche Ag | Sulfonamide derivatives as chymase inhibitors |
| EP2131655B1 (en) | 2007-03-02 | 2014-05-07 | The University of Tennessee Research Foundation | Tri-aryl/heteroaromatic cannabinoids and use thereof |
| EP2336125B1 (en) | 2008-04-11 | 2013-01-09 | Janssen Pharmaceutica N.V. | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase |
| WO2010075273A1 (en) | 2008-12-23 | 2010-07-01 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
| FR2945531A1 (fr) * | 2009-05-12 | 2010-11-19 | Sanofi Aventis | Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique |
| BRPI1012205A2 (pt) | 2009-05-14 | 2019-04-02 | Janssen Pharmaceutica Nv | compostos com duas porções heteroarila bicíclica fundidas como moduladores de leucotrieno a4 hidrolase |
| BR112013007566A2 (pt) | 2010-09-28 | 2016-08-02 | Panacea Biotec Ltd | novos compostos bicíclicos |
| GB201103419D0 (show.php) * | 2011-02-28 | 2011-04-13 | Univ Aberdeen | |
| MX359634B (es) | 2011-12-21 | 2018-10-03 | Novira Therapeutics Inc | Agentes antivirales contra la hepatitis b. |
| UY34992A (es) | 2012-08-28 | 2014-02-28 | Janssen R & D Ireland | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b |
| PT2961732T (pt) | 2013-02-28 | 2017-06-26 | Janssen Sciences Ireland Uc | Sulfamoil-arilamidas e utilização das mesmas como medicamentos para o tratamento de hepatite b |
| WO2014165128A2 (en) | 2013-03-12 | 2014-10-09 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
| WO2014161888A1 (en) | 2013-04-03 | 2014-10-09 | Janssen R&D Ireland | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| PT2997019T (pt) | 2013-05-17 | 2018-11-21 | Janssen Sciences Ireland Uc | Derivados de sulfamoíltiofenamida e o seu uso como medicamentos para o tratamento da hepatite b |
| UA118680C2 (uk) | 2013-07-25 | 2019-02-25 | ЯНССЕН САЙЄНСЕЗ АЙРЛЕНД ЮСі | Похідні заміщеного гліоксамідом піроламіду та їхнє застосування як лікарських препаратів для лікування гепатиту в |
| EP3060547B1 (en) | 2013-10-23 | 2017-10-11 | Janssen Sciences Ireland UC | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| RU2702109C1 (ru) | 2014-02-05 | 2019-10-04 | Новира Терапьютикс, Инк. | Комбинированная терапия для лечения инфекций вгв |
| EA035848B1 (ru) | 2014-02-06 | 2020-08-20 | Янссен Сайенсиз Айрлэнд Юси | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b |
| US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
| AU2016232801A1 (en) | 2015-03-19 | 2017-10-12 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis B infections |
| CN104898325A (zh) * | 2015-05-18 | 2015-09-09 | 深圳市华星光电技术有限公司 | 一种液晶显示面板及装置 |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| AR106192A1 (es) | 2015-09-29 | 2017-12-20 | Novira Therapeutics Inc | Formas cristalinas de un agente antiviral contra la hepatitis b |
| SG11201808949SA (en) | 2016-04-15 | 2018-11-29 | Novira Therapeutics Inc | Combinations and methods comprising a capsid assembly inhibitor |
| EP3749667A1 (en) | 2018-02-05 | 2020-12-16 | Alkermes, Inc. | Compounds for the treatment of pain |
| WO2019175657A1 (en) | 2018-03-14 | 2019-09-19 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
| CN113454077A (zh) | 2019-02-22 | 2021-09-28 | 爱尔兰詹森科学公司 | 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物 |
| MA55879A (fr) | 2019-05-06 | 2022-03-16 | Janssen Sciences Ireland Unlimited Co | Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b |
| KR20220034739A (ko) | 2019-05-31 | 2022-03-18 | 이케나 온콜로지, 인코포레이티드 | Tead 억제제 및 이의 용도 |
| WO2020243415A2 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CN112516138B (zh) * | 2020-12-15 | 2022-03-29 | 中国人民解放军陆军军医大学 | 化合物yx-2102在制备治疗肺纤维化药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5338753A (en) * | 1992-07-14 | 1994-08-16 | Sumner H. Burstein | (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics |
| FR2714057B1 (fr) * | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
| IT1271266B (it) * | 1994-12-14 | 1997-05-27 | Valle Francesco Della | Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi |
| US5532237A (en) * | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
| FR2735774B1 (fr) * | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
| FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| CA2245586A1 (en) * | 1996-02-06 | 1997-08-14 | Japan Tobacco Inc. | Novel compounds and pharmaceutical use thereof |
| WO1998041519A1 (en) * | 1997-03-18 | 1998-09-24 | Smithkline Beecham Corporation | Novel cannabinoid receptor agonists |
| TW200302088A (en) * | 2001-11-14 | 2003-08-01 | Schering Corp | Cannabinoid receptor ligands |
| MXPA06004279A (es) | 2003-10-14 | 2006-06-28 | Pfizer Prod Inc | Derivados biciclicos [3.1.0] como inhibidores del transportador de glicina. |
-
2005
- 2005-06-21 JP JP2007518192A patent/JP2008503585A/ja not_active Withdrawn
- 2005-06-21 AT AT05766578T patent/ATE444066T1/de not_active IP Right Cessation
- 2005-06-21 WO PCT/US2005/021870 patent/WO2006002133A1/en not_active Ceased
- 2005-06-21 CN CNA2005800284680A patent/CN101005838A/zh active Pending
- 2005-06-21 CA CA002571058A patent/CA2571058A1/en not_active Abandoned
- 2005-06-21 EP EP05766578A patent/EP1768667B1/en not_active Expired - Lifetime
- 2005-06-21 MX MX2007000015A patent/MX2007000015A/es active IP Right Grant
- 2005-06-21 ES ES05766578T patent/ES2332416T3/es not_active Expired - Lifetime
- 2005-06-21 US US11/157,510 patent/US7750158B2/en not_active Expired - Fee Related
- 2005-06-21 DE DE602005016929T patent/DE602005016929D1/de not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008503585A5 (show.php) | ||
| CN104520288B (zh) | 作为ccr9拮抗剂的吡唑‑1‑基苯磺酰胺 | |
| RU2376293C2 (ru) | Производные пиридазин-3(2h)-она и их применение в качестве ингибиторов фдэ4 | |
| CN109715624B (zh) | 用于治疗hbv感染的新颖治疗剂 | |
| KR101644170B1 (ko) | 씨알티에이치2 길항제 활성을 갖는 화합물 | |
| JP6506836B2 (ja) | Ｂ型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン | |
| JP4393195B2 (ja) | ４−（１，３，４−チアジアゾール−２−イル）−１，４−ジアザビシクロ−［３．２．２］ノナン誘導体、それらの製造およびそれらの治療的使用 | |
| JP4001542B2 (ja) | Ｎ−アルキル−アダマンチルトリアジニルベンズアミド誘導体 | |
| US7183413B2 (en) | Aminoquinoline compounds | |
| JP2007513915A5 (show.php) | ||
| JP2008513498A5 (show.php) | ||
| JP2006512313A5 (show.php) | ||
| KR102345381B1 (ko) | 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물 | |
| JP2013542996A5 (show.php) | ||
| JP2004528295A (ja) | キナーゼ阻害方法 | |
| JP2007529486A5 (show.php) | ||
| JP2006507355A5 (show.php) | ||
| JP2006503048A5 (show.php) | ||
| CN103228643B (zh) | 作为组胺h4受体配体的苯并唑衍生物 | |
| GB2407318A (en) | Substituted Indol-3-yl acetic acid derivatives | |
| WO2006069525A1 (en) | Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof | |
| JP2006512293A5 (show.php) | ||
| JP2005527521A5 (show.php) | ||
| JP2002504925A (ja) | Ｐｄｅ ｉｖおよび／又はｔｎｆインヒビターとしてのキノリン誘導体 | |
| JP2006507347A5 (show.php) |